Kailera Therapeutics
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 year.
- Recent price momentum is -36.9% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 6.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 11.58
- Open
- 11.37
- Day range
- 11.00 - 11.87
- Avg price
- 11.23
- Volume
- 553.33K
- Turnover
- 6.21M
- Turnover ratei
- 0.95%
- Volume ratioi
- 0.94
- Amplitudei
- 7.51%
- 52-week rangei
- 9.76 - 28.23
Valuation
- P/Ei
- -1,574.29
- P/E (TTM)i
- -4.89
- P/Bi
- 1.39
- EPSi
- -0.01
- Book value / shi
- 7.94
- Net profit
- -908.95K
- Net assets
- 1.03B
Share structure
- Market cap
- 1.43B
- Float capi
- 644.43M
- Shares out
- 129.85M
- Float sharesi
- 58.48M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2026-04-17
61.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+8.08M net over the window
Short interest
- Shares short
- 8.16M
- % of floati
- 6.30%
- Days to coveri
- 7.85
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Kailera Therapeutics (KLRA)?
Kailera Therapeutics last traded at 11.02. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Kailera Therapeutics's market cap?
About 1.43B.
What is the P/E ratio of Kailera Therapeutics?
The trailing twelve-month P/E is -4.89. The Valuation tab shows it against the stock's own five-year range.
Does Kailera Therapeutics pay a dividend?
Kailera Therapeutics does not currently pay a regular dividend.
Is Kailera Therapeutics a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 50.50, which implies 358.3% upside from the current price. This is not investment advice.
What is Kailera Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Kailera Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Kailera Therapeutics discussion 0 comments